Drug Development: The role of innovation in drug development (original) (raw)

• Commentary
• Published: 01 December 1997

Nature Biotechnology volume 15, pages 1318–1319 (1997)Cite this article

• 2294 Accesses
• 137 Citations
• 20 Altmetric
• Metrics details

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

• Three Dimensional Bioprinting for Hepatic Tissue Engineering: From In Vitro Models to Clinical Applications

  • Meghana Kasturi
  • , Vidhi Mathur
  • … Kirthanashri S. Vasanthan
    Tissue Engineering and Regenerative Medicine Open Access 26 October 2023

Access options

Subscribe to this journal

Receive 12 print issues and online access

$209.00 per year

only $17.42 per issue

Buy this article

• Purchase on SpringerLink
• Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

• Log in
• Learn about institutional subscriptions
• Read our FAQs
• Contact customer support

References

1. Human disease—From genetic causes to biochemical effects. Proceedings of the Roche Symposium “The Genetic Basis of Human Disease”, October 2–3, 1996, Basel. Drews, J. and Ryser, S. (eds.) Ex Libris Roche 9. Blackwell Science, Berlin.
2. Lifton, R. Human disease—From genetic causes to biochemical effects. Proceedings of the Roche Symposium “The Genetic Basis of Human Disease”, October 2–3, 1996, Basel. Drews, J. and Ryser, S. (eds.) Ex Libris Roche 9. Blackwell Science, Berlin.
3. Weber, W. 1997. pp. 10–11 in Pharmacogenetics. Oxford Univ. Press, New York and Oxford.
   Google Scholar
4. Ohsako, S. and Deguchi, T. 1990. J. Biol. Chem. 265: 4630–4634.
   CAS PubMed Google Scholar
5. Weber, W. 1997. pp. 12–13 in Pharmacogenetics. Oxford Univ. Press, New York and Oxford.
   Google Scholar
6. Mossinghoff, G.J. 1995. Drug Info. J. 29: 1077–1090.
   Article Google Scholar
7. Drews, J. and Ryser, S. 1997. Drug Discovery Today 2: 365–372.
   Article Google Scholar
8. It is obvious that these constraints are entirely dependent on a set of financial assumptions relating to costs, sales and discount rates for R&D expenditures. If these assumptions are modified, if for instance the discount rates after launch are lowered from 14% to 8% or if only out of pocket expenses are taken into account and opportunity costs altogether neglected, the picture brightens considerably. Eventually, such changes may have to be made.

Download references

Author information

Authors and Affiliations

1. president of global research and Stefan Ryser is chief of international research staff, Hoffmann-La Roche, CH-4002, Basel, Switzerland
   Jürgen Drews & Stefan Ryser

Authors

1. Jürgen Drews
   You can also search for this author inPubMed Google Scholar
2. Stefan Ryser
   You can also search for this author inPubMed Google Scholar

Rights and permissions

About this article

Cite this article

Drews, J., Ryser, S. Drug Development: The role of innovation in drug development.Nat Biotechnol 15, 1318–1319 (1997). https://doi.org/10.1038/nbt1297-1318

Download citation

• Issue Date: 01 December 1997
• DOI: https://doi.org/10.1038/nbt1297-1318

This article is cited by